| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.4 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.055 | 0.4 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.4 |